Answers are grounded in this paper and cite their sources.
Investigates CH25H inhibition to improve inflammation and function in aged hematopoietic stem cells, indicating a potential therapeutic approach.
Chronic inflammation and epigenetic dysregulation contribute to hematopoietic stem cell (HSC) aging, yet the underlying mechanisms remain incompletely defined. Here, by integrating H3K4me3 ChIP-seq and RNA-seq datasets from young and aged human HSCs, we identify cholesterol 25-hydroxylase (CH25H) as an epigenetically upregulated gene in aged HSCs. CH25H is upregulated at both the transcript and protein levels in aged mouse and human HSCs, accompanied by increased production of its enzymatic product, 25-hydroxycholesterol (25-HC), a bioactive oxysterol implicated in inflammatory signaling. To interrogate the CH25H–25-HC axis, we perform structure-based virtual screening and identify Kukoamine A (KuA) as a candidate CH25H inhibitor, which we validate using a cellular thermal shift assay. Functionally, KuA reduces 25-HC production, attenuates inflammatory signaling, including NF-κB and IL-1β pathways, and partially restores a youthful transcriptional profile in aged HSCs. KuA also suppresses poly(I:C)-induced inflammatory activation and oxidative stress, and improves lymphoid differentiation potential and colony-forming capacity. Collectively, these findings identify CH25H as an epigenetically activated inflammatory regulator in aged HSCs and suggest that targeting the CH25H–25-HC axis may alleviate inflammatory stress and improve function of aged HSC.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: